Radiation Oncology Associated Group

Oncología radioterápica-02

Summary of activities

Radiation Oncology is a medical specialty, with a specific scope in multidisciplinary management environments, dedicated to diagnostic aspects, clinical care, and more specifically therapeutic care of the oncological patient, primarily oriented to the use of radiation treatments and associated treatments. It is therefore a branch of clinical medicine that uses ionising radiation, alone or in combination with other therapeutic modalities, for the treatment of cancer and sometimes other non-neoplastic diseases.

Contributions to society

All scientific activities carried out by the Radiation Oncology group are directly aimed at benefiting patients and society. In recent years, advances in information technology have enabled major technological developments that have significantly improved the precision of radiation therapy treatments. These include three-dimensional imaging, automated segmentation of organs at risk, Image-Guided Radiation Therapy (IGRT), and Surface-Guided Radiation Therapy (SGRT), all of which contribute to higher-quality treatment delivery.

These improvements in precision have made it possible to safely deliver higher radiation doses per fraction while accurately conforming the prescribed dose to the target volume and better sparing surrounding healthy tissues, thereby improving patient outcomes and reducing treatment-related toxicity. Furthermore, treatment schedules have been substantially shortened, reducing the number of treatment sessions from 28-30 fractions to as few as 3-10 fractions in selected indications, while simultaneously increasing the biological effectiveness of treatment.

Collaborations

• Medical Oncology:
• Therapeutic combinations involving new drugs, targeted therapies and new radio sensitising agents for the local management of cancer. Current research programmes include next-generation immunotherapeutic agents for the treatment of lung cancer.
• Combination strategies using chemotherapeutic agents, such as trabectedin together with radiotherapy, within the multidisciplinary management of soft tissue sarcomas.
• Development and evaluation of predictors of treatment response to assess therapeutic efficacy in specific malignancies, including the use of radiomics in rectal and lung cancer.
• Collaborative approaches involving Medical Oncology, Radiology and Digestive Surgery for organ preservation strategies and conservative management of rectal cancer.
• Development and implementation of systems for process automation aimed at improving treatment efficiency, quality and patient safety.

PhD Theses

Oncología radioterápica-03

List of publications

Total neoadjuvant therapy in rectal cancer: The FOREST protocol, a patient-centered approach that clusters two cohorts with different outcomes.

Guadalajara H, Domínguez-Tristancho JL, Mateo RF, Leon-Arellano M, Sanz-Baro R, Geraldi E, Hormigo-Sanchez AI, Megías VMC, Cobos MP, Miras PM, Zulueta BL, Garcia-Arranz M, Foncillas JG, Caramés C, García-Olmo D.

Int J Cancer. 2026 Feb 01.158(3):697-706.

PMID: 40947902

FI: 4,7

http://dx.doi.org/10.1002/ijc.70126

Stereotactic radiosurgery practice patterns for brain metastases: a survey by the SRS_SBRT_SEOR (Spanish Society of Radiation Oncology) Working Group.

Ciérvide R, Manchón R, Ángel D, Quiles B, Rodríguez G, Veiras M, Blanco J, Diaz FM, Del Portillo EG, Monroy JL, Larrea L, Expósito J, Aristu J, Benavente S, Corrales-García E, Prieto C, García ME, Payano S, Perez MJ, Miguel IS, De la Pinta C, Díaz L, Mascias VM, Villarreal CLM, López M, Martínez FJ, Peña M, García R.

Rep Pract Oncol Radiother. 2025.30(4):513-522.

PMID: 41195103

FI: 2

http://dx.doi.org/10.5603/rpor.107739

Results of radical treatment of locally advanced rectal cancer in geriatric and non-geriatric patients.

Ocanto A, Cantero R, Morera R, Ramírez R, Rodríguez I, Castillo K, Samper P, Couñago F.

Rep Pract Oncol Radiother. 2025.30(1):54-61.

PMID: 40242422

FI: 2

http://dx.doi.org/10.5603/rpor.104387

Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR.

Sosa-Fajardo P, Martín-Martín M, Luna-Tirado J, López-Guerra JL, Gomis-Sellés E, López-Mata M, Valtueña-Peydró G, Santos-Rodríguez M, Álvarez-González AM, Potdevin-Stein G, Martín-Barrientos P, Kannemann A, Farré-Bernadó N, González-Portillo E, Manso-Lema A, Rodríguez-Roldán M, González-Ruiz MÁ, Wals-Zurita A, Linares-Mesa NA, Garduño-Sánchez S, Barrionuevo-Castillo P, Moreno-Fuentes B, Martos-Alcalde M, Simón-Silva P, Peña-Perea MT, Blanco-Villar ML, Vera-Barragán V, Ocanto-Martínez A, Mateos-Domínguez M, Vallejo-Ocaña C, Hernanz-Lucas R, Castro-Gómez JE, Peña-Huertas M, Duque-Santana V, Zapatero-Ortuño J, García-Torres C, Valencia-Nieto P, Diezhandino-García P, Eito-Valdovinos C, Olarte-García A, Guerrero-Gómez LL, Sánchez-García S, Bobo-Jaureguizar A, Sotoca-Ruiz A, Vázquez-Barreiro B, Cameselle-Gallego G, Flamarique-Andueza S, Rico-Oses M, Guijarro-Verdu M, Montijano-Linde M, Guzmán-Gómez L, Bezares-Alarcón AB, Cigarral-García C, Moreno-Ceano P, Serrano-Andreu J, Murcia-Mejía M, Pagola-Divassón M, Casas-Duran F, Almendros-Blanco P, Pedraza-Fernández S, González-Ferreira JA, Alcántara P, Couñago F, GOECP Group.

Cancers (Basel). 2025 Nov 27.17(23).

PMID: 41375008

FI: 4,4

http://dx.doi.org/10.3390/cancers17233807

Management of high-risk prostate cancer in Spain: results from a national patterns of care survey.

Duque-Santana V, Gómez-Aparicio MA, Ocanto A, Selles EG, Gaztañaga M, Willisch P, Pijoan XM, Blanco-Villar ML, Henriquez I, Lara PC, Ribeiro I, Ramirez AG, Valcárcel ML, de Manzanos IVF, Echagüen SP, Martínez PA, Barragán VV, Millán CV, Vacas AI, Ots PMS, Glaría Enríquez LA, Luis AM, Niño LM, Del Castillo Acuña R, Del Portillo EG, Ferrer F, Gómez-Iturriaga A, Conde Moreno AJ, Del Cerro Peñalver E, Couñago F, López-Campos F, URONCOR investigators.

Clin Transl Oncol. 2025 Oct 29.

PMID: 41160367

FI: 2,5

http://dx.doi.org/10.1007/s12094-025-04078-7

The Rising Impact of HPV Infection in the Antiretroviral Therapy (ART) Era.

Asensi-Díaz E, Carrillo I, Al-Hayani A, Mejías-Ledesma M, Guadalajara H, Azinovic I, Trsitancho JLD, Vidal LS, Castellano V, García-Olmo D, Górgolas M, Cabello-Úbeda A.

Curr HIV Res. 2025 Oct 14.

PMID: 41102961

FI: 1

http://dx.doi.org/10.2174/011570162X381694250925045507

Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial.

González San Segundo C, López-Campos F, Gómez Iturriaga A, Santos M, Ocanto A, Montezuma L, Boladeras-Inglada AM, Glaria L, Guardado S, Rodríguez A, Henríquez I, Olivera J, Duque-Santana V, Garre J, Moreno S, Valero J, Conde AJ, Doval A, Sancho G, Martin Nieto P, Castaño Cantos A, García N, Fernández Alonso S, García García R, Díaz Gavela A, Buchser D, Maldonado X, Mases J, Hernando Requejo O, Sanmamed N, Martínez Salamanca JI, Couñago F.

Actas Urol Esp (Engl Ed). 2025 Sep.49(7):501823.

PMID: 40752730

FI: 1,2

http://dx.doi.org/10.1016/j.acuroe.2025.501823

Diffuse large B-cell lymphoma presenting as acute adrenal hemorrhage.

Torres F, Suárez U, Pizano P.

Blood Res. 2025 Mar 19.60(1):18.

PMID: 40106058

FI: 2,8

http://dx.doi.org/10.1007/s44313-025-00064-8